恩帕吉菲
期限（时间）
医学
疾病
肾脏疾病
内科学
重症监护医学
糖尿病
内分泌学
2型糖尿病
物理
量子力学
作者
William G. Herrington,Natalie Staplin,Nikita Agrawal,Christoph Wanner,Jennifer B. Green,Sibylle J. Hauske,Jonathan Emberson,David Preiss,Parminder K. Judge,Doreen Zhu,Rejive Dayanandan,Ryoki Arimoto,Kaitlin J. Mayne,Sarah Y A Ng,Emily Sammons,Michael Hill,Will Stevens,Karl Wallendszus,Susanne Brenner,Alfred K. Cheung
标识
DOI：10.1056/nejmoa2409183
摘要
In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial follow-up was designed to assess how the effects of empagliflozin would evolve after the discontinuation of the trial drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI
cdercder
冰魂
pluto
SYLH
不倦
eee
bc
昏睡的蟠桃
剑指东方是为谁
科研助手6
文献看不懂
归尘
遇上就这样吧
wy.he
back you up
YifanWang
8R60d8
单纯的文龙
科研小民工
HeWang
皖公网安备34019202002308
